CNBX Pharmaceuticals Inc. (CNBX) stock
CNBXOTCPharmaceutical PreparationsFiscal year ends August 31
$0.00+0.00 (0.00%)
Close on Oct 19, 2026Market cap $197.79KP/E –Yield –
CNBX Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
CNBX Pharmaceuticals's R&D Expenses for the twelve months ending Feb 28, 2026 was $0. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $1.77M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Aug 31, 2025 | $0 | -100.0% |
| FY2024 | Aug 31, 2024 | $194.79K | -54.9% |
| FY2023 | Aug 31, 2023 | $431.57K | -63.5% |
| FY2022 | Aug 31, 2022 | $1.18M | -33.2% |
| FY2021 | Aug 31, 2021 | $1.77M | +5.3% |
| FY2020 | Aug 31, 2020 | $1.68M | +9.0% |
| FY2019 | Aug 31, 2019 | $1.54M | +53.8% |
| FY2018 | Aug 31, 2018 | $1.00M | +306.5% |
| FY2017 | Aug 31, 2017 | $246.94K | +39.0% |
| FY2016 | Aug 31, 2016 | $177.61K | +27.4% |
| FY2015 | Aug 31, 2015 | $139.44K | – |
| FY2014 | Aug 31, 2014 | $0 | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ1 2026 | Feb 28, 2026 | $0 | – |
| Q1 FY2026CQ4 2025 | Nov 30, 2025 | $0 | – |
| Q4 FY2025CQ3 2025 | Aug 31, 2025 | $0 | -100.0% |
| Q3 FY2025CQ2 2025 | May 31, 2025 | $0 | -100.0% |
| Q2 FY2025CQ1 2025 | Feb 28, 2025 | $0 | -100.0% |
| Q1 FY2025CQ4 2024 | Nov 30, 2024 | $0 | -100.0% |
| Q3 FY2024CQ2 2024 | May 31, 2024 | $42.88K | -83.7% |
| Q2 FY2024CQ1 2024 | Feb 29, 2024 | $107.20K | +769.6% |
| Q1 FY2024CQ4 2023 | Nov 30, 2023 | $112.42K | +78.8% |
| Q4 FY2023CQ3 2023 | Aug 31, 2023 | $93.24K | -43.0% |
| Q3 FY2023CQ2 2023 | May 31, 2023 | $263.12K | +5.6% |
| Q2 FY2023CQ1 2023 | Feb 28, 2023 | $12.33K | -96.3% |
| Q1 FY2023CQ4 2022 | Nov 30, 2022 | $62.89K | -85.7% |
| Q4 FY2022CQ3 2022 | Aug 31, 2022 | $163.60K | -65.3% |
| Q3 FY2022CQ2 2022 | May 31, 2022 | $249.06K | -54.8% |
| Q2 FY2022CQ1 2022 | Feb 28, 2022 | $330.58K | +4.6% |
| Q1 FY2022CQ4 2021 | Nov 30, 2021 | $440.04K | +1.5% |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | $471.00K | +17.2% |
| Q3 FY2021CQ2 2021 | May 31, 2021 | $550.84K | +48.8% |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | $315.96K | -28.9% |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | $433.73K | -6.9% |
| Q4 FY2020CQ3 2020 | Aug 31, 2020 | $401.93K | -15.9% |
| Q3 FY2020CQ2 2020 | May 31, 2020 | $370.08K | +10.9% |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | $444.42K | +3.8% |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | $466.03K | +53.2% |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | $477.77K | +13.0% |
| Q3 FY2019CQ2 2019 | May 31, 2019 | $333.76K | +26.7% |
| Q2 FY2019CQ1 2019 | Feb 28, 2019 | $428.04K | +306.7% |
| Q1 FY2019CQ4 2018 | Nov 30, 2018 | $304.18K | +43.3% |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | $422.85K | +284.0% |
| Q3 FY2018CQ2 2018 | May 31, 2018 | $263.51K | +286.5% |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | $105.24K | +126.2% |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | $212.31K | +859.2% |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | $110.11K | +100.0% |
| Q3 FY2017CQ2 2017 | May 31, 2017 | $68.17K | – |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | $46.53K | – |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | $22.13K | – |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | $55.05K | – |
See a number that looks wrong?